NASDAQIndustrialsElectrical Equipment & PartsSnapshot 2026-10-23
The long-term thesis, the evidence coming in, and the environment around it. Thesis dated Jul 8, 2026.
Next-FY EPS estimate change · 30 days
A matching fiscal period and sufficient coverage are required.
One observable signal. This measures changing earnings expectations, not the probability of a gain or loss.
The calculation requires same-period, same-provider snapshots, positive EPS, at least five analysts and a baseline within three days of the requested lookback.
| Measure / period | Management expectations | Analyst expectations |
|---|---|---|
| Quarter ending 2026-12-30 | ||
| Revenue | — | 61.5M |
| EPS | — | 0.27 |
| Annual ending 2026-12-31 | ||
| Revenue | — | 224.9M |
| EPS | — | 0.86 |
Management figures unavailable.
4 published thesis conditions, with dated milestones shown separately.
| Key Factor | Why It Matters | Current Status | Break Condition | Latest Evidence |
|---|---|---|---|---|
Support strategic capital expenditures to enhance growth | The company invests in new products and strategic capital spending. | Intact | significant reduction in capital expenditures | Qualitative condition This condition has no defined numerical measure. Context reviewed through Oct 23, 2026Last status assessment Oct 24, 2026Compare required operating outcomesCompare scope, accounting basis and period before treating this evidence as progress against an annual requirement. Management contextStated as a priority in 2 of last 2 quarters. Long-term debt declined from $44.2M in 2026-Q1 to $42.9M in 2026-Q2, indicating some progress in debt reduction. Management continues to emphasize supporting strategic capital expenditures funded by incremental cash flow, showing delivering trajectory. Delivery assessment Oct 24, 2026 |
Sustain investment in new product development | A supporting condition in Ultralife Corp's published investment case. The stated target is continue strategic R&D spending. | Intact | significant cuts to R&D investment | Qualitative condition This condition has no defined numerical measure. Context reviewed through Oct 23, 2026Last status assessment Oct 24, 2026Compare required operating outcomesCompare scope, accounting basis and period before treating this evidence as progress against an annual requirement. Management contextStated as a priority in 2 of last 2 quarters. R&D expenses increased from $2.3M in 2026-Q1 to $3.2M in 2026-Q2, reflecting continued investment in new product development. Management consistently highlights this investment as key to future growth, showing delivering trajectory. Delivery assessment Oct 24, 2026 |
Restore profitability and generate positive net income | Ultralife aims to restore profitability and generate cash flow. | Improving | net income remains negative through FY26 | Net income: $2.543M FY2026-Q2; GAAP. Published target: net income > 0. Target period is not explicitly aligned with this observation. Source published Aug 7, 20262,543,000 USD · source valueSource reportLast status assessment Oct 24, 2026Measurement sourceconsolidated · GAAP FY2026-Q2 · Period ending Jun 30, 2026 Source: company_financial_results. Reference: ea7f56eb-b082-4448-8a32-77e34a1e5899. Source status: eligible. Compare scope, accounting basis and period before treating this evidence as progress against an annual requirement. Management contextStated as a priority in 2 of last 2 quarters. Revenue was stable at $47.4M in 2026-Q1 and $47.9M in 2026-Q2. Net income improved from a loss of $451K in 2026-Q1 to a profit of $2.54M in 2026-Q2. Management is delivering on restoring profitability and generating cash flow with improving operating income and backlog. Delivery assessment Oct 24, 2026 |
Achieve revenue growth near $225 million | Analysts expect revenue near $225 million and EPS of $0.93 in 2026. | Under Pressure | revenue falls below $200 million in FY26 | Revenue: $47.943M FY2026-Q2; GAAP. Published target: revenue >= $224.9 million. Target period is not explicitly aligned with this observation. Source published Aug 7, 202647,943,000 USD · source valueSource reportLast status assessment Oct 24, 2026Measurement sourceconsolidated · GAAP FY2026-Q2 · Period ending Jun 30, 2026 Source: company_financial_results. Reference: ea7f56eb-b082-4448-8a32-77e34a1e5899. Source status: eligible. Compare scope, accounting basis and period before treating this evidence as progress against an annual requirement. |
Stored thesis · Jul 8, 2026. Latest Evidence uses source-matched measurements where available, alongside the last thesis-monitor assessment. Source periods and assessment dates are shown separately. A new measurement does not automatically change the published status or verify an older target.
Compare these dated observations with the operating requirements above
Comparable estimate history is unavailable.
Revenue and EPS estimates track expectations. They are not delivered results or like-for-like proof of a required annual path.
Compare required revenue and earningsMonthly analyst history is unavailable.
Recent actions · Sep 25–Oct 24 · 0 recorded
Individual price-target observations are unavailable.
0 raises · 0 cuts · 0 unchanged · 0 without a comparable prior
Sep 25, 2026–Oct 24, 2026. Each firm's latest positive target is paired only with its immediately prior positive target from the same provider, at most 180 days earlier. Unmatched observations have one dot; conflicting observations are not compared.
The evidence, the remaining questions, and what comes next
No recovery evidence is reported in the available driver assessments.
Nov 17, 2026
Look for updated results and guidance against the published targets, plus direct evidence for unresolved drivers.
Review earnings4 of 4 published conditions remain under pressure or need verification. The next results need to address those conditions.
The dated weekly assessment and its assumptions are available in Read detailed Outlook.
Observed price history; separate from operating scenarios
The weekly editorial context below is a separate assessment from the dated monitor evidence above. Recovery observations do not automatically change the published thesis. Unverified outside influences are hypotheses, not measured driver evidence.
This is a turnaround-style business thesis, with early evidence of improving profitability and cash generation. The multi-year view remains uncertain: management priorities are mostly on track, while company momentum has weakened and recent results remain below its industry cohort.
The valuation evidence is mixed: ULBI is described as cheap versus peers, but also tagged as stretched, with a low-confidence model. The expectations gap is positive, but the evidence does not explain precisely what the market assumes; there is also no indication that pricing is especially fragile.
Near term, the risk of another earnings miss is elevated after misses in three recent reports, and a guidance cut would be a meaningful negative. Over the multi-year view, stable revenue and a move from a quarterly loss to a profit support the profitability-restoration thesis, while investment in new products continues; debt reduction and capital spending progress are mixed.
The next call matters: guidance and continued profit and cash-flow progress will test whether the recent improvement can persist. The sector backdrop is a headwind, and results from industrial bellwethers ETN, VRT, and BE could signal whether sector support strengthens or fades.
For the 1-3 year view, ULBI offers a tentative recovery thesis, not a settled one: improving quarterly profitability is offset by repeated misses, weaker momentum, and elevated risk. Not investment advice.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.